Tobin Schilke - Mar 15, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: Chief Financial Officer
Signature: /s/ Terri McDowell, Attorney-in-Fact
Stock symbol: RVNC
Transactions as of: Mar 15, 2022
Transactions value $: -$41,165
Form type: 4
Date filed: 3/17/2022, 05:48 PM
Previous filing: Feb 17, 2022
Next filing: Jul 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	-$41.2K	-2.61K	-4%	$15.79	62.5K	Mar 15, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.

Content

Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.